Everolimus Dosage and Dosage Guidelines

Everolimus (Afinitor) is an effective drug used to treat a variety of cancers, and its use and dosing guidelines are critical to ensuring patient safety and treatment effectiveness.

Everolimus is an oral medication and should be taken by mouth. Patients can take it with or without food, but it is recommended to take it at the same time every day to maintain the stability of blood levels. Everolimus tablets should be swallowed whole and should not be chewed or crushed. If the patient is unable to swallow the tablet, the tablet can be placed in a glass of water (approximately 30ml), stir gently until completely dissolved (approximately 7 minutes) and then take it immediately. Then rinse the cup with the same volume of water and take the entire rinse to ensure the complete dose is ingested. Everolimus should be continued until intolerable toxicity occurs as long as the patient obtains clinical benefit from treatment.

For patients with advanced renal cell carcinoma, advanced neuroendocrine tumors, and tuberous sclerosis-related renal angiomyolipoma, the recommended dose is 10 mg once daily. For patients with tuberous sclerosis-associated subependymal giant cell astrocytoma, the recommended dose is 4.5 mg/m² once daily.

When serious or intolerable adverse reactions are encountered, it may be necessary to temporarily reduce the dosage or interrupt treatment. Recommended dose reduction is approximately one-half of the previously administered dose. If the reduced dose is below the lowest available tablet strength, dosing every other day may be considered.

No dosage adjustment is required in patients with renal impairment as renal impairment is not expected to affect drug exposure.

Patients with hepatic impairment may require a dose reduction to 5 mg or 2.5 mg once daily, depending on the severity of the liver injury.

The dose of everolimus may need to be adjusted if coadministered with inhibitors or inducers of certain enzymes that affect drug metabolism (e.g.CYP3A4).